

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |                                                          |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------|--|
| <b>REPORT DOCUMENTATION PAGE</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  | <i>Form Approved</i><br><i>OMB No. 0704-0188</i>         |  |
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b> |  |                                                          |  |
| <b>1. REPORT DATE</b> 28- 07-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  | <b>2. REPORT TYPE</b><br><b>FINAL</b>                    |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | <b>3. DATES COVERED</b><br>1 August 2011 – 31 March 2016 |  |
| <b>4. TITLE AND SUBTITLE</b><br><br>Cranial Electrotherapy Stimulation (CES) in Soldiers with Insomnia: A Pilot Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  | <b>5a. CONTRACT NUMBER</b><br>N/A                        |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | <b>5b. GRANT NUMBER</b><br>HU0001-11-1-TS12              |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | <b>5c. PROGRAM ELEMENT NUMBER</b><br>N/A                 |  |
| <b>6. AUTHOR(S)</b><br><br>Betty Garner, PhD, Nurse Research Scientist, Army NC, USN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  | <b>5d. PROJECT NUMBER</b><br>N11-C09                     |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | <b>5e. TASK NUMBER</b><br>N/A                            |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | <b>5f. WORK UNIT NUMBER</b><br>N/A                       |  |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br><br>Landstuhl Regional Medical Center<br>CMR 402 PO BOX 1187<br>APO, AE, Germany, 09180                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b><br>N/A   |  |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>TriService Nursing Research Program, 4301 Jones Bridge RD<br>Bethesda, MD 20814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b><br>TSNRP         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | <b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b> N11-C09    |  |
| <b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b><br><br>Approved for public release; distribution unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |  |                                                          |  |
| <b>13. SUPPLEMENTARY NOTES</b><br>N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  |                                                          |  |

**14. ABSTRACT**

**Purpose:** 1. Test feasibility and acceptability of Cranial Electrotherapy Stimulation (CES) for insomnia. 2. Evaluate extent of change in pre- and post-treatment sleep measures.

**Design:** A double-blind randomized controlled, parallel design to compare the effect of CES to Sham.

**Methods:** Subjects received 10 intervention sessions over a 2-week period (randomized to Active CES or Sham treatment) and completed 1-month follow-up surveys. Subjects completed questionnaires at baseline, immediately after treatment, and one month after treatment. Sleep diaries were recorded for 1 week prior to intervention, concurrently during the 2 weeks of intervention, and for 1 week at the 1-month follow-up.

**Sample:** A convenience sample of military beneficiaries with insomnia in a non-deployed environment.

**Analysis:** 1. Feasibility and acceptability were assessed through comparing the number of subjects and missed sessions throughout the study, as well as by participant expectancy. 2. To evaluate the extent of change pre- and post-treatment sleep measures, both a 2 x 2 and a 2 x 3 mixed ANOVA were conducted.

**Findings:** 1. 27 of 230 individuals screened were allocated to the intervention, of which 3 withdrew; thus, 24 were randomized to CES or Sham groups. For acceptability, the CES group had significantly higher means than the Sham group for 2 of 4 expectancy items. 2. Overall, the self-reported extent of change as measured by the total Insomnia Severity Index (ISI) score and sleep parameters of Pittsburgh Sleep Diary, though not significant, had a more appreciable improvement over time for the CES group.

**15. SUBJECT TERMS**

Cranial Electrotherapy Stimulation (CES), insomnia, post-treatment sleep, sleep diary, Military

**16. SECURITY CLASSIFICATION OF:**

**a. REPORT**  
UNCLASSIFIED

**b. ABSTRACT**  
UNCLASSIFIED

**c. THIS PAGE**  
UNCLASSIFIED

**17. LIMITATION  
OF ABSTRACT**

UU

**18. NUMBER  
OF PAGES**

24

**19a. NAME OF RESPONSIBLE PERSON**  
Jaya POther

**19b. TELEPHONE NUMBER** (include area  
code)  
301-319-0596

**TriService Nursing Research Program Final Report Cover Page**

|                                                                  |                                                                                   |
|------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Sponsoring Institution                                           | TriService Nursing Research Program                                               |
| Address of Sponsoring Institution                                | 4301 Jones Bridge Road<br>Bethesda MD 20814                                       |
| USU Grant Number                                                 | HU0001-11-1-TS12                                                                  |
| USU Project Number                                               | N11-C09                                                                           |
| Title of Research Study or Evidence-Based Practice (EBP) Project | Cranial Electrotherapy Stimulation (CES) in Soldiers with Insomnia: A Pilot Study |
| Period of Award                                                  | 1 August 2011 – 31 March 2016                                                     |
| Applicant Organization                                           | The Geneva Foundation                                                             |
| Address of Applicant Organization                                | 917 Pacific Ave, Suite 600, Tacoma WA 98402                                       |

**Principal Investigator (PI) Military Contact Information**


|                  |                          |
|------------------|--------------------------|
| Duty Title       | [REDACTED]               |
| Address          | [REDACTED]<br>[REDACTED] |
| Telephone        | [REDACTED]               |
| Mobile Telephone | [REDACTED]               |
| E-mail Address   | [REDACTED]               |

**PI Home Contact Information**

|                  |                          |
|------------------|--------------------------|
| Address          | [REDACTED]<br>[REDACTED] |
| Mobile Telephone | [REDACTED]               |
| E-mail Address   | [REDACTED]               |

**Signatures**

PI Signature



Date

July 28, 2016

Mentor Signature



Date

July 11, 2016

## **Table of Contents**

|                                                                                                                                          |      |
|------------------------------------------------------------------------------------------------------------------------------------------|------|
| Cover Page                                                                                                                               | 1    |
| Abstract                                                                                                                                 | 3    |
| TSNRP Research Priorities that Study or Project Addresses                                                                                | 4    |
| Progress Towards Achievement of Specific Aims of the Study or Project                                                                    | 5-16 |
| Significance of Study or Project Results to Military Nursing                                                                             | 17   |
| Changes in Clinical Practice, Leadership, Management, Education, Policy, and/or<br>Military Doctrine that Resulted from Study or Project | 18   |
| References Cited                                                                                                                         | 19   |
| Summary of Dissemination                                                                                                                 | 20   |
| Reportable Outcomes                                                                                                                      | 21   |
| Recruitment and Retention Table                                                                                                          | 22   |
| Demographic Characteristics of the Sample                                                                                                | 23   |
| Final Budget Report                                                                                                                      | 24   |

### **Abstract**

**Purpose:** 1. Test feasibility and acceptability of Cranial Electrotherapy Stimulation (CES) for insomnia. 2. Evaluate extent of change in pre- and post-treatment sleep measures.

**Design:** A double-blind randomized controlled, parallel design to compare the effect of CES to Sham.

**Methods:** Subjects received 10 intervention sessions over a 2-week period (randomized to Active CES or Sham treatment) and completed 1-month follow-up surveys. Subjects completed questionnaires at baseline, immediately after treatment, and one month after treatment. Sleep diaries were recorded for 1 week prior to intervention, concurrently during the 2 weeks of intervention, and for 1 week at the 1-month follow-up.

**Sample:** A convenience sample of military beneficiaries with insomnia in a non-deployed environment.

**Analysis:** 1. Feasibility and acceptability were assessed through comparing the number of subjects and missed sessions throughout the study, as well as by participant expectancy. 2. To evaluate the extent of change pre- and post-treatment sleep measures, both a 2 x 2 and a 2 x 3 mixed ANOVA were conducted.

**Findings:** 1. 27 of 230 individuals screened were allocated to the intervention, of which 3 withdrew; thus, 24 were randomized to CES or Sham groups. For acceptability, the CES group had significantly higher means than the Sham group for 2 of 4 expectancy items. 2. Overall, the self-reported extent of change as measured by the total Insomnia Severity Index (ISI) score and sleep parameters of Pittsburgh Sleep Diary, though not significant, had a more appreciable improvement over time for the CES group.

**Implications for Military Nursing:** Although the trends showed an overall improvement in self-reported sleep measures, the feasibility of recruiting subjects with pure insomnia provided a challenge in achieving adequate numbers for statistical relevance. Other lessons learned included optimization of recruitment and communication methods based on the movement of the military community.

**TSNRP Research Priorities that Study or Project Addresses****Primary Priority**

|                                    |                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Force Health Protection:           | <input checked="" type="checkbox"/> Fit and ready force<br><input type="checkbox"/> Deploy with and care for the warrior<br><input type="checkbox"/> Care for all entrusted to our care                                                                                                                                           |
| Nursing Competencies and Practice: | <input type="checkbox"/> Patient outcomes<br><input type="checkbox"/> Quality and safety<br><input type="checkbox"/> Translate research into practice/evidence-based practice<br><input type="checkbox"/> Clinical excellence<br><input type="checkbox"/> Knowledge management<br><input type="checkbox"/> Education and training |
| Leadership, Ethics, and Mentoring: | <input type="checkbox"/> Health policy<br><input type="checkbox"/> Recruitment and retention<br><input type="checkbox"/> Preparing tomorrow's leaders<br><input type="checkbox"/> Care of the caregiver                                                                                                                           |
| Other:                             | <input type="checkbox"/>                                                                                                                                                                                                                                                                                                          |

**Secondary Priority**

|                                    |                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Force Health Protection:           | <input type="checkbox"/> Fit and ready force<br><input type="checkbox"/> Deploy with and care for the warrior<br><input checked="" type="checkbox"/> Care for all entrusted to our care                                                                                                                                           |
| Nursing Competencies and Practice: | <input type="checkbox"/> Patient outcomes<br><input type="checkbox"/> Quality and safety<br><input type="checkbox"/> Translate research into practice/evidence-based practice<br><input type="checkbox"/> Clinical excellence<br><input type="checkbox"/> Knowledge management<br><input type="checkbox"/> Education and training |
| Leadership, Ethics, and Mentoring: | <input type="checkbox"/> Health policy<br><input type="checkbox"/> Recruitment and retention<br><input type="checkbox"/> Preparing tomorrow's leaders<br><input type="checkbox"/> Care of the caregiver                                                                                                                           |
| Other:                             | <input type="checkbox"/>                                                                                                                                                                                                                                                                                                          |

## **Progress Towards Achievement of Specific Aims of the Study or Project**


### **Findings related to each specific aim, research or study questions, and/or hypothesis:**

*Question #1: Is conducting CES therapy feasible (e.g. recruitment, prescreening, consent, randomization, and retention) and acceptable (e.g. number of missed sessions and participant expectancy) treatment protocol for soldiers with insomnia?*

**Feasibility** was assessed using the number of subjects who completed the phone screen, met the eligibility screening, returned the questionnaires, and completed the study.

- Recruitment began in February 2011, was put on hold from July 2011 to July 2012 due to deployment of the PI, and then continued through December 2014 until very few potential subjects would call to be screened and none were deemed eligible.
- Of 230 screened, 174 were screening failures or lost to contact. Of the 55 who consented, 17 were screening failures and 2 withdrew. Of the 36 screened by the psychologist, 6 were screening failures, and 3 were no-shows or lost to follow-up. Of the 27 allocated to the intervention, 3 subjects withdrew prior to the start of the intervention. Of the 24 that completed the baseline assessments at Time1 and started the intervention, 1 withdrew during the intervention due to worsening of sleep disturbance. Thus, 23 completed the immediate post-assessment at Time2. Of these 19 out of 23 completed the 1-month post-assessment at Time3 as 4 were lost after Time2. Of the 19 who completed Time3, all completed the questionnaires but only 14 completed the sleep diary. Thus, a total of 14 participants, out of a goal of 50, completed all data collection phases of the study. See Diagram 1.

Diagram 1. CES Consort Flowchart





**Acceptability** was assessed by the number of missed sessions and participant expectancy.


- Only 1 participant from the Sham group withdrew during the intervention after stating that sleep was getting worse. One participant did not complete the 1-month follow-up visit (ISI and sleep diary) and an additional 8 did not complete the final sleep diary.
- Expectancy was measured by the four items extracted from the Borkovec and Nau (B & N) Questionnaire and the two groups (CES vs. Sham) were compared. Significant between group differences were found for two of the items (via both parametric and nonparametric testing) with the CES group obtaining higher means (and mean ranks) than the Sham group on the following items: (a) “how logical is the treatment” ( $Z = -2.62$ ,  $p = .009$ ) and (b) “Recommend this treatment to a friend” ( $Z = -2.41$ ,  $p = .016$ ).

*Question #2: Does the use of CES improve the immediate and short-term effects (1 month after treatment) on pre-and post-treatment self-reported sleep outcomes as measured by the total Insomnia Severity Index score and sleep parameters of Pittsburgh Sleep Diary (sleep efficiency, sleep onset latency, number of awakenings, wake after sleep onset, and overall sleep quality)?*

The focus of the analysis was on comparing the two groups: Active (CES Treatment) vs. Sham (control) across three phases of measurement: baseline (Time1; Active  $n = 12$  and Sham  $n = 12$ ), immediate after treatments/post-assessment (Time2; Active  $n = 12$  and Sham  $n = 11$ ) and 1-month post-assessment (Time3; Active  $n = 11$  and Sham  $n = 8$ ). Given missing data at the last phase of data collection (1 ISI and 9 sleep diaries), the summary of results includes both a  $2 \times 2$  (first two phases, Time1 and Time2) and  $2 \times 3$  (all three phases, Time1-Time3) analysis.


- The two-way interaction for the **summed ISI total score** is not significant:  $F(1,21) = 1.39$ ,  $p = .251$  ( $\eta^2 = .062$ ). The main effect for time is significant:  $F(1,21) = 15.47$ ,  $p = .001$  ( $\eta^2 = .424$ ) indicating, when aggregating across the two groups, a higher estimated mean is obtained at baseline Time1 ( $M = 16.30$ ) than following treatment Time2: ( $M = 10.89$ ). The main effect for group was not significant ( $p = .199$ ,  $\eta^2 = .077$ ). Though the interaction was not significant, the pattern of means was such that a more appreciable decrease in the total ISI score was obtained for the Active group than the Sham group.

For the  $2 \times 3$  mixed ANOVA, the two-way (first order) interaction is not significant:  $F(2, 34) = .84$ ,  $p = .44$  ( $\eta^2 = .047$ ). The main effect for time is significant:  $F(2,21) = 8.53$ ,  $p = .001$  ( $\eta^2 = .324$ ) indicating, when aggregating across the two groups, a higher estimated mean is obtained at baseline Time1 ( $M = 16.22$ ) than following treatment Time2: ( $M = 11.05$ ) and post-treatment Time3 ( $M = 10.99$ ). The main effect for group was not significant ( $p = .158$ ,  $\eta^2 = .114$ ). Though the interaction was not significant, the pattern of means was such that a more appreciable decrease in the total ISI score was obtained for the Active group than the Sham group across the first two waves of data collection.




- The 2 x 2 interaction for **Sleep Efficiency** (SE) is not significant:  $F(1,21) = .48, p = .497$  ( $\eta^2 = .022$ ). The main effect for time is significant:  $F(1,21) = 5.64, p = .027$  ( $\eta^2 = .212$ ) indicating, when aggregating across the two groups, a higher estimated mean is obtained at after treatment Time2 ( $M = 92.61$ ) than baseline Time1: ( $M = 89.99$ ). The main effect for group was not significant ( $p = .964, \eta^2 < .001$ ). Though the interaction was not significant, a more appreciable increase in the SE score was obtained for the Active group than the Sham group.

For the 2 x 3 analysis, comparing the two groups using the baseline Time1, following treatment Time 2, and post-treatment Time 3 measures, the two-way (first order) interaction is not significant:  $F(2, 24) = .58, p = .57$  ( $\eta^2 = .046$ ). Neither of the main effects were significant for time ( $p = .278, \eta^2 = .101$ ) and group ( $p = .672, \eta^2 = .016$ ). Though the interaction was not significant, the pattern of means was such that a more appreciable increase in the SE score was obtained for the Active group whereas for the Sham group there was an increased score following treatment Time2 and then a slight decrease for the post-treatment Time3.




- The 2 x 2 two-way interaction for **Sleep Onset Latency (SOL)** is not significant:  $F(1,21) = .32$ ,  $p = .579$  ( $\eta^2 = .015$ ). The main effects for time ( $p = .099$ ,  $\eta^2 = .124$ ) and group were not significant ( $p = .932$ ,  $\eta^2 < .001$ ). Though not significant, a more appreciable decrease in the SOL was obtained for the Active group than the Sham group.

For the 2 x 3 interaction, the two-way (first order) interaction is not significant:  $F(2,21) = .66$ ,  $p = .524$  ( $\eta^2 = .052$ ). The main effects for time ( $p = .435$ ,  $\eta^2 = .067$ ) and group were not significant ( $p = .715$ ,  $\eta^2 = .012$ ). Though not significant, the pattern of means was such that the Active group had a higher mean at the Time1, approximately the same as the Sham group at Time2, and then the appreciative mean at Time3.




- The two-way interaction for **Number of Awakenings (NAWAK)** is not significant:  $F(1,21) = .77$ ,  $p = .39$  ( $\eta^2 = .035$ ). The main effect for time is significant:  $F(1,21) = 6.95$ ,  $p = .015$  ( $\eta^2 = .25$ ) indicating, when aggregating across the two groups, a higher estimated mean is obtained at baseline ( $M = 2.02$ ) than following treatment: ( $M = 1.61$ ). The main effect for group was not significant ( $p = .692$ ,  $\eta^2 = .008$ ). Though not significant, the pattern of means was such that a more appreciable decrease in NAWAK was obtained for the Active group than the Sham group.

For the 2 x 3 interaction, the two-way (first order) interaction is not significant:  $F(2, 24) = 1.49$ ,  $p = .245$  ( $\eta^2 = .111$ ). The main effect for time is significant:  $F(2,24) = 3.94$ ,  $p = .033$  ( $\eta^2 = .247$ ) indicating, when aggregating across the two groups, the highest estimated mean is obtained at baseline ( $M = 1.99$ ) with subsequent decreases across each successive wave of measurement ( $M = 1.83$  for Time2 and  $M = 1.50$  for Time3). The main effect for group was not significant ( $p = .401$ ,  $\eta^2 = .059$ ). Though not significant, there was a decrease in the means for both groups with a more appreciable decrease for the Sham group.




- The 2 x 2 two –way interaction for **Wake After Sleep Onset (WASO)** is not significant:  $F(1, 16) = 3.45$ ,  $p = .082$  ( $\eta^2 = .177$ ). The main effects for time ( $p = .082$ ,  $\eta^2 = .177$ ) and group were not significant ( $p = .273$ ,  $\eta^2 = .075$ ). Though not significant, the pattern of means was such that there was a substantive decrease in the WASO score across time for the Active group whereas similar scores are obtained across time for the Sham group.

The 2 x 3 interaction the two-way (first order) interaction is not significant:  $F(2, 12) = .36$ ,  $p = .708$  ( $\eta^2 = .056$ ). The main effect for time ( $p = .712$ ,  $\eta^2 = .055$ ) was not significant, but there was significance for the group main effect (aggregating across time):  $F(1, 5) = 10.34$ ,  $p = .018$  ( $\eta^2 = .075$ ) with a higher estimated mean for the Sham group ( $M = 51.41$ ) than the Active group ( $M = 18.81$ ). Though not significant, the pattern of means was such that there was a substantive decrease in the WASO score across time for the Active group whereas for the Sham group there was a slight decrease at Time2 then increase at Time3. Note that there was significant group main effect (aggregating across time with a higher estimated mean for the Sham group than the Active group).



- The 2 x 2 two –way interaction for **Overall Sleep Quality (SQ)** is not significant:  $F(1,21) = 2.71$ ,  $p = .115$  ( $\eta^2 = .114$ ). The main effect for time is significant:  $F(1,21) = 28.26$ ,  $p < .001$  ( $\eta^2 = .574$ ) indicating, when aggregating across the two groups, a lower estimated mean is obtained at Time1 baseline ( $M = 4.75$ ) than Time2: ( $M = 5.93$ ). The main effect for group was not significant ( $p = .846$ ,  $\eta^2 = .002$ ). Though not significant, the pattern of means was such that a more appreciable increase in Overall SQ was obtained for the Sham group than the Active group across the two waves of data collection.

For the 2 x 3 interaction the two-way (first order) interaction is not significant:  $F(2,21) = .23$ ,  $p = .779$  ( $\eta^2 = .019$ ). The main effect for time is significant:  $F(1,21) = 5.91$ ,  $p = .008$  ( $\eta^2 = .33$ ) indicating, when aggregating across the two groups, a lower estimated mean is obtained at Time1 baseline ( $M = 4.68$ ) and then similar higher means at Time2 ( $M = 5.84$ ) and Time3 ( $M = 5.83$ ). The main effect for group was not significant ( $p = .291$ ,  $\eta^2 = .092$ ). Though not significant, the pattern of means was such that there are successively higher means in Overall SQ for the Active group whereas there is a slight decrease at the Post-TX measure for the Sham group.



*Question #3: Describe socio-demographic characteristics (including rank) and other factors (trait anxiety, state anxiety, family and self-history of insomnia, perceived stress, frequency and length of deployment, and sleep hygiene) as potential predictors of a successful treatment response.*

Multiple regression was used to predict the Insomnia Severity Index (ISI) with a set of predictors for this aim. Given the small sample size, it was decided to pare down the number of predictors, and conduct analysis separately at each wave of data collection. The variables to be used as predictors are as follows:

1. Self history of sleep problems: will only use history of insomnia
2. Trait anxiety (TSTAI)
3. Perceived stress (PSS)
4. Group (treatment/active vs. control/sham)

- When conducting hierarchical regression with **ISI at Time1 as the outcome**, at the first step of variable entry (i.e., history of insomnia, PSS, and TSTAI),  $R^2 = .153$  (i.e., 15.3% of the variability is accounted for in explaining the outcome). Though that is what would be considered to be a medium effect size in multiple regression, significance was not obtained. At the 2nd step of variable entry (i.e., the grouping variable) the incremental variability was only  $R^2 = .01$  and it was not significant. 15.4% of the variability was accounted for by the full model. When examining the partial regression coefficients at both steps of variable entry, no variables were significant. However, history of insomnia had the largest bivariate correlation ( $r = .3$ ) and partial correlation ( $r_p = .292$ ) at the final step of variable entry. Also, improvement in model fit (though significance still not obtained) was obtained when nonlinear terms for PSS and TSTAI were added to the model, and also, when an outlying residual from the initial model was omitted.

**Model Summary<sup>c</sup>**

| Model | R                 | R Square | Adjusted R Square | Std. Error of the Estimate | Change Statistics |          |     |     |               |
|-------|-------------------|----------|-------------------|----------------------------|-------------------|----------|-----|-----|---------------|
|       |                   |          |                   |                            | R Square Change   | F Change | df1 | df2 | Sig. F Change |
| 1     | .391 <sup>a</sup> | .153     | .026              | 2.59091                    | .153              | 1.202    | 3   | 20  | .335          |
| 2     | .392 <sup>b</sup> | .154     | -.025             | 2.65685                    | .001              | .020     | 1   | 19  | .890          |

a. Predictors: (Constant), PSS\_sc Perceived Stress Scale-10 summed scale score, SelfInsomnia Sleep History--Self: Insomnia, TSTAI\_sc Trait state trait anxiety Index Summed scale score

b. Predictors: (Constant), PSS\_sc Perceived Stress Scale-10 summed scale score, SelfInsomnia Sleep History--Self: Insomnia, TSTAI\_sc Trait state trait anxiety Index Summed scale score, Group

c. Dependent Variable: ISI\_sc Insomnia Severity Index Summed Scale Score (Baseline)

**Coefficients<sup>a</sup>**

| Model |                                                             | Unstandardized Coefficients |            | Standardized Coefficients | t     | Sig. | 95.0% Confidence Interval for B |             | Correlations |         |      | Collinearity Statistics |       |
|-------|-------------------------------------------------------------|-----------------------------|------------|---------------------------|-------|------|---------------------------------|-------------|--------------|---------|------|-------------------------|-------|
|       |                                                             | B                           | Std. Error | Beta                      |       |      | Lower Bound                     | Upper Bound | Zero-order   | Partial | Part | Tolerance               | VIF   |
| 1     | (Constant)                                                  | 13.207                      | 2.747      |                           | 4.807 | .000 | 7.476                           | 18.938      |              |         |      |                         |       |
|       | SelfInsomnia Sleep History--Self: Insomnia                  | 1.454                       | 1.067      | .282                      | 1.363 | .188 | -.771                           | 3.680       | .300         | .292    | .281 | .990                    | 1.010 |
|       | TSTAI_sc Trait state trait anxiety Index Summed scale score | .046                        | .093       | .129                      | .502  | .621 | -.147                           | .240        | .228         | .111    | .103 | .640                    | 1.562 |
|       | PSS_sc Perceived Stress Scale-10 summed scale score         | .059                        | .100       | .152                      | .588  | .563 | -.149                           | .267        | .256         | .130    | .121 | .635                    | 1.574 |
| 2     | (Constant)                                                  | 13.151                      | 2.846      |                           | 4.620 | .000 | 7.193                           | 19.108      |              |         |      |                         |       |
|       | SelfInsomnia Sleep History--Self: Insomnia                  | 1.472                       | 1.101      | .285                      | 1.337 | .197 | -.833                           | 3.777       | .300         | .293    | .282 | .977                    | 1.024 |
|       | TSTAI_sc Trait state trait anxiety Index Summed scale score | .047                        | .095       | .130                      | .494  | .627 | -.152                           | .246        | .228         | .113    | .104 | .640                    | 1.563 |
|       | PSS_sc Perceived Stress Scale-10 summed scale score         | .055                        | .106       | .142                      | .521  | .609 | -.166                           | .276        | .256         | .119    | .110 | .596                    | 1.679 |
|       | Group                                                       | .159                        | 1.136      | .031                      | .140  | .890 | -2.220                          | 2.537       | .065         | .032    | .029 | .911                    | 1.098 |

a. Dependent Variable: ISI\_sc Insomnia Severity Index Summed Scale Score (Baseline)

- When conducting hierarchical regression with **ISI at Time2 as the outcome**, at the first step of variable entry (i.e., history of insomnia, PSS, and TSTAI),  $R^2 = .078$  (i.e., 7.8% of the variability is accounted for in explaining the outcome) and significance was not obtained. At the 2nd step of variable entry (i.e., the grouping variable) the incremental variability was  $R^2 = .061$  and it was not significant. 13.9% of the variability was accounted for by the full model. When examining the partial regression coefficients at both steps of variable entry, no variables were significant. However, the grouping variable had the largest bivariate correlation ( $r = -.29$ ) and partial correlation ( $r_p = .258$ ) at the final step of variable entry. Also, as documented in the report, improvement in model fit (though significance still not obtained) was obtained when nonlinear terms for PSS and TSTAI were added to the model.

**Model Summary<sup>c</sup>**

| Model | R                 | R Square | Adjusted R Square | Std. Error of the Estimate | Change Statistics |          |     |     |               |
|-------|-------------------|----------|-------------------|----------------------------|-------------------|----------|-----|-----|---------------|
|       |                   |          |                   |                            | R Square Change   | F Change | df1 | df2 | Sig. F Change |
| 1     | .279 <sup>a</sup> | .078     | -.068             | 5.65496                    | .078              | .536     | 3   | 19  | .664          |
| 2     | .373 <sup>b</sup> | .139     | -.052             | 5.61385                    | .061              | 1.279    | 1   | 18  | .273          |

a. Predictors: (Constant), PSS2\_sc Perceived Stress Scale-10 summed scale score (Posttime 2), SelfInsomnia Sleep History--Self: Insomnia, TSTAI\_sc Trait state trait anxiety Index Summed scale score

b. Predictors: (Constant), PSS2\_sc Perceived Stress Scale-10 summed scale score (Posttime 2), SelfInsomnia Sleep History--Self: Insomnia, TSTAI\_sc Trait state trait anxiety Index Summed scale score, Group

c. Dependent Variable: ISI2\_sc Insomnia Severity Index Summed Scale Score (PostTime 2)

**Coefficients<sup>a</sup>**

| Model |                                                                   | Unstandardized Coefficients |            | Standardized Coefficients | t      | Sig. | 95.0% Confidence Interval for B |             | Correlations |         |       | Collinearity Statistics |       |
|-------|-------------------------------------------------------------------|-----------------------------|------------|---------------------------|--------|------|---------------------------------|-------------|--------------|---------|-------|-------------------------|-------|
|       |                                                                   | B                           | Std. Error | Beta                      |        |      | Lower Bound                     | Upper Bound | Zero-order   | Partial | Part  | Tolerance               | VIF   |
| 1     | (Constant)                                                        | 17.631                      | 6.189      |                           | 2.849  | .010 | 4.677                           | 30.585      |              |         |       |                         |       |
|       | SelfInsomnia Sleep History--Self: Insomnia                        | -1.301                      | 2.381      | -.120                     | -.547  | .591 | -6.284                          | 3.681       | -.113        | -.124   | -.120 | .998                    | 1.002 |
|       | TSTAI_sc Trait state trait anxiety Index Summed scale score       | -.169                       | .217       | -.223                     | -.777  | .447 | -.623                           | .286        | -.250        | -.175   | -.171 | .587                    | 1.703 |
|       | PSS2_sc Perceived Stress Scale-10 summed scale score (Posttime 2) | -.052                       | .323       | -.047                     | -.162  | .873 | -.727                           | .623        | -.185        | -.037   | -.036 | .587                    | 1.704 |
| 2     | (Constant)                                                        | 18.290                      | 6.172      |                           | 2.963  | .008 | 5.323                           | 31.256      |              |         |       |                         |       |
|       | SelfInsomnia Sleep History--Self: Insomnia                        | -1.373                      | 2.364      | -.127                     | -.581  | .569 | -6.340                          | 3.594       | -.113        | -.136   | -.127 | .998                    | 1.002 |
|       | TSTAI_sc Trait state trait anxiety Index Summed scale score       | -.169                       | .215       | -.224                     | -.786  | .442 | -.622                           | .283        | -.250        | -.182   | -.172 | .587                    | 1.703 |
|       | PSS2_sc Perceived Stress Scale-10 summed scale score (Posttime 2) | .041                        | .331       | .037                      | .124   | .902 | -.654                           | .736        | -.185        | .029    | .027  | .550                    | 1.817 |
|       | Group                                                             | -2.796                      | 2.472      | -.261                     | -1.131 | .273 | -7.989                          | 2.397       | -.290        | -.258   | -.247 | .899                    | 1.113 |

a. Dependent Variable: ISI2\_sc Insomnia Severity Index Summed Scale Score (PostTime 2)

- When conducting hierarchical regression with **ISI at Time3 as the outcome** at the first step of variable entry (i.e., history of insomnia, PSS, and TSTAI),  $R^2 = .26$  and though it is a relatively large effect size for multiple regression, significance was not obtained. At the 2nd step of variable entry (i.e., the grouping variable) the incremental variability was  $R^2 = .088$  and it was not significant. 34.8% of the variability was accounted for by the full model. When examining the partial regression coefficients at both steps of variable entry, the TSTAI total score was significant at both the first and second step of variable entry and it also yielded the largest bivariate correlation ( $r = -.502$ ) and partial correlation ( $r_p = -.508$ ) at the final step of variable entry.

**Model Summary<sup>c</sup>**

| Model | R                 | R Square | Adjusted R Square | Std. Error of the Estimate | Change Statistics |          |     |     |               |
|-------|-------------------|----------|-------------------|----------------------------|-------------------|----------|-----|-----|---------------|
|       |                   |          |                   |                            | R Square Change   | F Change | df1 | df2 | Sig. F Change |
| 1     | .510 <sup>a</sup> | .260     | .113              | 4.74355                    | .260              | 1.761    | 3   | 15  | .198          |
| 2     | .590 <sup>b</sup> | .348     | .162              | 4.60965                    | .088              | 1.884    | 1   | 14  | .191          |

a. Predictors: (Constant), PSS3\_sc Perceived Stress Scale-10 summed scale score (Posttime 3), SelfInsomnia Sleep History--Self: Insomnia, TSTAI\_sc Trait state trait anxiety Index Summed scale score

b. Predictors: (Constant), PSS3\_sc Perceived Stress Scale-10 summed scale score (Posttime 3), SelfInsomnia Sleep History--Self: Insomnia, TSTAI\_sc Trait state trait anxiety Index Summed scale score, Group

c. Dependent Variable: ISI3\_sc Insomnia Severity Index Summed Scale Score (PostTime 3)


**Coefficients<sup>a</sup>**

| Model | Unstandardized Coefficients                                       |            | Standardized Coefficients | t     | Sig.   | 95.0% Confidence Interval for B |             | Correlations |         |       | Collinearity Statistics |       |
|-------|-------------------------------------------------------------------|------------|---------------------------|-------|--------|---------------------------------|-------------|--------------|---------|-------|-------------------------|-------|
|       | B                                                                 | Std. Error | Beta                      |       |        | Lower Bound                     | Upper Bound | Zero-order   | Partial | Part  | Tolerance               | VIF   |
| 1     | (Constant)                                                        | 22.386     | 5.291                     | 4.231 | .001   | 11.107                          | 33.664      |              |         |       |                         |       |
|       | Selfinsomnia Sleep History--Self: Insomnia                        | .014       | 2.186                     | .001  | .995   | -4.645                          | 4.673       | -.026        | .002    | .001  | .994                    | 1.006 |
|       | TSTAI_sc Trait state trait anxiety Index Summed scale score       | -.362      | .162                      | -.543 | .041   | -.707                           | -.016       | -.502        | -.499   | -.495 | .833                    | 1.200 |
|       | PSS3_sc Perceived Stress Scale-10 summed scale score (Posttime 3) | .081       | .196                      | .100  | .411   | -.337                           | .499        | -.121        | .106    | .091  | .833                    | 1.201 |
| 2     | (Constant)                                                        | 23.393     | 5.194                     | 4.504 | .000   | 12.253                          | 34.533      |              |         |       |                         |       |
|       | Selfinsomnia Sleep History--Self: Insomnia                        | -.156      | 2.128                     | -.016 | .073   | -4.720                          | 4.408       | -.026        | -.020   | -.016 | .991                    | 1.009 |
|       | TSTAI_sc Trait state trait anxiety Index Summed scale score       | -.348      | .158                      | -.522 | .045   | -.686                           | -.009       | -.502        | -.508   | -.476 | .830                    | 1.205 |
|       | PSS3_sc Perceived Stress Scale-10 summed scale score (Posttime 3) | .111       | .192                      | .138  | .581   | -.300                           | .523        | -.121        | .153    | .125  | .821                    | 1.218 |
|       | Group                                                             | -2.985     | 2.175                     | -.301 | -1.373 | -7.649                          | 1.679       | -.340        | -.344   | -.296 | .970                    | 1.031 |

a. Dependent Variable: ISI3\_sc Insomnia Severity Index Summed Scale Score (PostTime 3)


*Supplemental data analysis was conducted for the Beck Anxiety Inventory (BAI), the Perceived Stress Scale (PSS), the State Trait Anxiety Inventory (STAI) and to test the relationship of group membership with self-report of history of insomnia.*

- For supplementary analysis for the Beck Anxiety Inventory (BAI), the 2 x 2 mixed ANOVA, comparing the two groups using the baseline Time1 and following treatment Time2 measures, the two-way (first order) interaction was not significant. The main effect for time was significant indicating, when aggregating across the two groups, a higher estimated mean is obtained at baseline Time1 ( $M = 5.91$ ) than following treatment Time2 ( $M = 3.36$ ). Both groups exhibited similar decrease in means over time. For the 2 x 3 mixed ANOVA (DV = BAI) the two-way (first order) interaction was not significant, but the main effect for time was *with* the highest estimated mean obtained at Time1 ( $M = 6.05$ ) and lowest at Time2 ( $M = 3.16$ ). Both groups exhibited similar trajectories excepting at the last wave of data collection there was a slight increase in the mean for the Active group and a decrease for the Sham group.





- For supplementary analysis for the Perceived Stress Scale (PSS), the 2 x 2 mixed ANOVA comparing the two groups using the baseline Time1 and following treatment Time2 measures, the two-way (first order) interaction is not significant. The main effect for time is significant indicating, when aggregating across the two groups, a higher estimated mean is obtained at Time1 ( $M = 12.30$ ) than Time2 ( $M = 9.22$ ). Both groups exhibited similar decrease in means over time. There were no significant effects for the 2 x 3 mixed ANOVA.



- For supplementary analysis for the State Trait Anxiety Inventory (STAI) the mean differences between the groups was not significant. Though not significant the Active group had a higher mean ( $M = 35.56$ ) than the Sham group ( $M = 33.54$ ).

#### Descriptive Statistics

Dependent Variable: TSTAI\_sc Trait state trait anxiety

| Group      | Mean    | Std. Deviation | N  |
|------------|---------|----------------|----|
| .0 Sham    | 33.5417 | 7.94143        | 12 |
| 1.0 Active | 35.5833 | 6.76163        | 12 |
| Total      | 34.5625 | 7.28804        | 24 |

- For supplementary analysis a 2 x 2 chi-squared test was conducted tested the relationship of group membership and self-report of history of insomnia. Though the findings were not significant, 50% ( $n = 6$ ) in the Sham group reported history of insomnia whereas 41.7% ( $n = 5$ ) in the Active group did so (Relative Risk = 1.2).

#### Effect of problems or obstacles on the results:

Low recruitment and retention rate affected the data analyses and overall implications of the findings for Question #2 and Question #3.

**Limitations:**

Limitations to the study are due to the strict inclusion criteria and intensive data collection in the study design, which hindered recruitment and retention of participants leading to not meeting the required number of participants per power analysis.

**Conclusion:**

While well received from the participants in the acceptability of the treatment modality, feasibility as evidenced by recruitment and retention was not optimal based on the strict criteria. Thus, the main lesson learned from this study is that “pure” insomniacs are far and a few between and insomnia is often a co-morbid condition.

Trends in the data for the small sample size, however, show an overall improvement in Insomnia Severity Index and the self-reported sleep parameters for the Active group over the Sham group (with an exception of the number of awakenings). Of note, when aggregating the group means for the ISI total score, SQ, and the BAI, the main effects for time were significant across the three phases of the study; potentially indicating that participation in the study (regardless of group) had an effect on the overall outcomes.

### **Significance of Study or Project Results to Military Nursing**

Insomnia is linked to impaired cognitive and immune functions, decreased quality of life, and increased accidents. Insomnia is well established in the general population both as a risk factor for and as a symptom PTSD, anxiety, and depression. CBT-I and pharmacotherapies are both efficacious treatments for the improvement of sleep. However, CBT-I is often time-consuming, requires trained clinicians or health care providers, and is not readily accessible. CBT-I requires that individuals keep a consistent daily sleep and wake schedule, which would be difficult for Service members deployed in war zones. Hypnotic drugs have undesirable side effects and are recommended primarily for a short-term use. These drugs are not ideal in a fast-paced environment with unpredictable sleeping conditions. Few data are available regarding soldiers with insomnia and no studies are available using a safe, portable device such as the CES in treatment of soldiers with insomnia. Hence, identification of insomnia and early treatment with a readily available, easy-to-use device with minimal adverse effects by military nurses and other healthcare providers can ensure timely treatment of soldiers with insomnia. This pilot study of treatment effect of CES is a first step in the development of research program with potential to assist in the management of insomnia and co-morbid conditions in soldiers.

**Changes in Clinical Practice, Leadership, Management, Education, Policy, and/or Military Doctrine that Resulted from Study or Project**

Nothing Significant to Report

**References Cited**

None

**Summary of Dissemination**

| <b>Type of Dissemination</b> | <b>Citation</b>                                                                                                                                                                                                                                                                                           | <b>Date and Source of Approval for Public Release</b>         |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Publications                 | None                                                                                                                                                                                                                                                                                                      |                                                               |
| Publications in Press        | None                                                                                                                                                                                                                                                                                                      |                                                               |
| Published Abstracts          | None                                                                                                                                                                                                                                                                                                      |                                                               |
| Podium Presentations         | <p>Hopkinson, S.<br/>Researching Complementary and Alternative Medicine for Sleep Disorders<br/>ERMC Fall Conference; Garmisch, Germany</p> <p>Garner, B.<br/>Cranial Electrotherapy Stimulation (CES) in Servicemembers with Insomnia: A Pilot Study<br/>TSNRP Dissemination Course; San Antonio, TX</p> | <p>Nov 2014 – LRMC PAO &amp; OPSEC</p> <p>Sep 2014 – OTSG</p> |
| Poster Presentations         | <p>Hopkinson, S., Garner, B., &amp; Ladwig, J.<br/>Cranial Electrotherapy Stimulation (CES) in Military Beneficiaries with Insomnia: A Pilot Study</p> <p>EAMNE—European African Military Nursing Exchange; Garmisch, Germany</p>                                                                         | Apr 2015 – LRMC PAO & OPSEC                                   |
| Media Reports                | None                                                                                                                                                                                                                                                                                                      |                                                               |
| Other                        | None                                                                                                                                                                                                                                                                                                      |                                                               |

**Reportable Outcomes**

| <b>Reportable Outcome</b>   | <b>Detailed Description</b> |
|-----------------------------|-----------------------------|
| Applied for Patent          | None                        |
| Issued a Patent             | None                        |
| Developed a cell line       | None                        |
| Developed a tissue or serum | None                        |
| Developed a data registry   | None                        |

**Recruitment and Retention Table**

| <b>Recruitment and Retention Aspect</b>                      | <b>Number</b> |
|--------------------------------------------------------------|---------------|
| Subjects Projected in Grant Application                      | 50            |
| Subjects Available                                           |               |
| Subjects Contacted or Reached by Approved Recruitment Method | 230           |
| Subjects Screened                                            | 230           |
| Subjects Ineligible                                          | 174           |
| Subjects Refused                                             | 0             |
| Human Subjects Consented                                     | 55            |
| Subjects Who Withdrew                                        | 1             |
| Subjects Who Completed Study                                 | 23            |
| Subjects With Complete Data                                  | 14            |
| Subjects with Incomplete Data                                | 9             |



### Demographic Characteristics of the Sample

| <b>Characteristic (Eligible for Intervention n = 27)</b> |          |
|----------------------------------------------------------|----------|
| Age (yrs)                                                | 40 ± 12  |
| Women, n (%)                                             | 13 (48%) |
| Race                                                     |          |
| White, n (%)                                             | 17 (63%) |
| Black, n (%)                                             | 7 (26%)  |
| Hispanic or Latino, n (%)                                | 3 (11%)  |
| Native Hawaiian or other Pacific Islander, n (%)         | 0 (0%)   |
| Asian, n (%)                                             | 0 (0%)   |
| Other, n (%)                                             | 0 (0%)   |
| Military Service or Civilian                             |          |
| Air Force, n (%)                                         | 12 (44%) |
| Army, n (%)                                              | 13 (48%) |
| Marine, n (%)                                            | 0 (0%)   |
| Navy, n (%)                                              | 1 (4%)   |
| Civilian, n (%)                                          | 0 (0%)   |
| Missing data, n (%)                                      | 1 (4%)   |
| Service Component                                        |          |
| Active Duty, n (%)                                       | 12 (44%) |
| Reserve, n (%)                                           | 1 (4%)   |
| National Guard, n (%)                                    | 6 (22%)  |
| Retired Military, n (%)                                  | 2 (7%)   |
| Prior Military but not Retired, n (%)                    | 0 (0%)   |
| Military Dependent, n (%)                                | 6 (22%)  |
| Civilian, n (%)                                          | 0 (0%)   |